Abeona Therapeutics Inc (NASDAQ:ABEO)’s share price hit a new 52-week low on Thursday . The stock traded as low as $9.54 and last traded at $9.77, with a volume of 28496 shares changing hands. The stock had previously closed at $10.03.
Several equities analysts have weighed in on the company. Zacks Investment Research raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday. Mizuho assumed coverage on Abeona Therapeutics in a report on Thursday, October 11th. They issued a “buy” rating and a $17.00 price objective for the company. ValuEngine cut Abeona Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, October 11th. BidaskClub cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, October 4th. Finally, Cantor Fitzgerald set a $36.00 price objective on Abeona Therapeutics and gave the company a “buy” rating in a report on Monday, October 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the stock. Abeona Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $26.80.
The company has a market cap of $613.67 million, a PE ratio of -14.89 and a beta of 1.10.
Institutional investors and hedge funds have recently modified their holdings of the company. Fortaleza Asset Management Inc. bought a new position in shares of Abeona Therapeutics in the 2nd quarter valued at $104,000. Parkside Advisors LLC bought a new stake in Abeona Therapeutics during the 3rd quarter worth $160,000. United Services Automobile Association bought a new stake in Abeona Therapeutics during the 2nd quarter worth $162,000. MetLife Investment Advisors LLC grew its position in Abeona Therapeutics by 57.8% during the 2nd quarter. MetLife Investment Advisors LLC now owns 19,333 shares of the biopharmaceutical company’s stock worth $309,000 after acquiring an additional 7,085 shares during the last quarter. Finally, Mesirow Financial Investment Management Inc. bought a new stake in Abeona Therapeutics during the 2nd quarter worth $348,000. Institutional investors own 76.24% of the company’s stock.
About Abeona Therapeutics (NASDAQ:ABEO)
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Recommended Story: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.